Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 79Triple Negative Breast Neoplasms 9Stomach Neoplasms 8Inflammatory Breast Neoplasms 6Carcinoma, Hepatocellular 6Non-Muscle Invasive Bladder Neoplasms 3Esophageal Neoplasms 3Sarcoma 2Primary Breast Cancer 2Pathologic Complete Response 2Lung Neoplasms 2Carcinoma, Ductal, Breast 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Resectable HER2-positive Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Nasopharyngeal Carcinoma 1Malignant mesenchymal tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

pembrolizumab 95Cisplatin 35Paclitaxel 27Carboplatin 27Docetaxel 17lenvatinib 15Fluorouracil 14Saline Solution 13Capecitabine 12Pemetrexed 10Gemcitabine 10Oxaliplatin 9Cetuximab 7Albumin-Bound Paclitaxel 7olaparib 6epacadostat 6Bevacizumab 6130-nm albumin-bound paclitaxel 6Leucovorin 5enzalutamide 4Etoposide 4trifluridine tipiracil drug combination 3regorafenib 3belzutifan 3Prednisone 3Irinotecan 3Glucose 3Dexamethasone 3liposomal doxorubicin 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Parkinson Disease 4, Autosomal Dominant Lewy Body × Epirubicin × Clear all
NCT06966700 2026-05-22

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Merck Sharp & Dohme LLC

Phase 3 Recruiting
2,400 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡